Epirubicin/cyclophosphamide Reactions 1680, p127 - 2 Dec 2017 Periaortitis: case report A 55-year-old woman developed periaortitis following treatment with epirubicin and cyclophosphamide. The woman was diagnosed with T2N1M1 stage IV breast carcinoma. She received chemotherapy with IV epirubicin 2 2 90 mg/m on day 1 and IV cyclophosphamide 600 mg/m on day 1. Her other medications included dexamethasone, aprepitant and palonosetron. She developed a high grade fever and stomatitis on day 11 after the initiation of the chemotherapy. Her WBC count was normal, but a severe inflammatory reaction was revealed by the laboratory data. The woman received unspecified antibiotic treatment on admission. During the clinical course, granulocytosis was noted. On day 14 of the initiation of chemotherapy, a CT scan did not reveal any findings relating to the fever’s origin. The elevated CRP values and fever were persistent. The WBC count rose to 14500/µL on day 20, but her condition was stable. She had complaints of back pain on day 25. A repeat CT scan revealed thickening of the rind surrounding the descending aorta along with bilateral pleural effusions. These findings were indicative of acute periaortitis. The examinations relating to connective tissue disease and vasculitis were normal. Antibiotic therapy was discontinued on day 20. Her fever resolved. Her WBC count also decreased. On day 33 after the initiation of chemotherapy, she was discharged. She then received chemotherapy with docetaxel, pertuzumab and trastuzumab. No inflammatory reactions were observed. On day 90, CT scan was performed, which revealed resolution of the thickened rind of the descending aorta. No aneurysmic changes were observed. Author comment: "We herein report a case of periaortitis with a high-grade fever during chemotherapy with epirubicin and cyclophosphamide for breast cancer." Inoue M, et al. Periaortitis induced by epirubicin and cyclophosphamide for a patient with advanced breast cancer. International Cancer Conference Journal 6: 180-183, No. 4, Oct 2017. Available from: URL: http://doi.org/10.1007/ s13691-017-0302-1 - Japan 803285058 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial